Overall, our results suggest that along with previously described abnormalities such as <i>TP53</i> mutations or monosomy7, 7q-, which are all absent in this patient, additional mechanisms including <i>IDH1</i> mutations drive SDS-related AML and are likely associated with variable outcomes. The gene discussed is TP53; the disease is acute myeloid leukemia.